Valion Bio VBIO
NASDAQ VBIO
$0.12 +0.00 (+0.41%)
At close: Aug 21, 2026 · 4:00 PM EDT

Valion Bio (VBIO) Operating Leases (2021 - 2026)

Valion Bio (VBIO) posted quarterly Operating Leases of $321000.0 for Q1 2024, down 0.62% year-over-year from $323000.0 in Q2 2023, and up 82.39% quarter-over-quarter from $176000.0 in Q4 2023.

Valion Bio (VBIO) Operating Leases (2021 - 2026) Analysis & Trends

Valion Bio's Operating Leases history runs 4 years deep, the most recent figure standing at $321000.0 for Q1 2024.

  • In Q1 2024, Operating Leases fell 0.62% year-over-year to $321000.0; the TTM figure through Mar 2024 stood at $321000.0 (down 0.62% YoY), while the FY2023 annual figure was $176000.0, down 52.04% from the prior year.
  • Operating Leases for Q1 2024 stood at $321000.0, up from $176000.0 in the prior quarter.
  • The five-year high for Operating Leases was $573000.0 in Q3 2022, with the low at $176000.0 in Q4 2023.
  • The 4-year median for Operating Leases is $345000.0 (2022), against an average of $378700.0.
  • The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 57.77% in 2023, then dropped 0.62% in 2024.
  • Valion Bio's Operating Leases stood at $545000.0 in 2021, then sank by 32.66% to $367000.0 in 2022, then sank by 52.04% to $176000.0 in 2023, then soared by 82.39% to $321000.0 in 2024.
  • Business Quant data shows VBIO's Operating Leases at $321000.0 in Q1 2024, $176000.0 in Q4 2023, and $242000.0 in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Valion Bio 405,599.63 -1.79 Mn -45,000.00

Historic Data

Download Data
DateValue
Jun 30, 2026 10.02 Mn
Mar 31, 2024 321,000.00
Dec 31, 2023 176,000.00
Sep 30, 2023 242,000.00
Jun 30, 2023 275,000.00
Mar 31, 2023 323,000.00
Dec 31, 2022 367,000.00
Sep 30, 2022 573,000.00
Jun 30, 2022 461,000.00
Mar 31, 2022 504,000.00
Dec 31, 2021 545,000.00